2013-10-07 11:48:07 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Tibet Rhodiola Pharmaceutical Holding Co (600211) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Tibet Rhodiola Pharmaceutical Holding Co (600211). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Tibet Rhodiola Pharmaceutical Holding Co investor.
Report Summary: Tibet Rhodiola Pharmaceutical Holding Co is a low quality company with a negative outlook. Tibet Rhodiola Pharmaceutical Holding Co has weak business growth and is run by passable management. The trend in Tibet Rhodiola Pharmaceutical Holding Co fair value exchange rate against its closest rated-competitor, China National Accord Medicines Corp Ltd, has been stable over the past 2 weeks. When compared to its closest competitor, Tibet Rhodiola Pharmaceutical Holding Co shows similar overvaluation and is
equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Tibet Rhodiola Pharmaceutical Holding Co for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.